General Information:

Id: 6,361 (click here to show other Interactions for entry)
Diseases: Diabetes mellitus, type II - [OMIM]
Hepatocellular carcinoma - [OMIM]
Insulin resistance
Mammalia
review
Reference: Ampuero J and Romero-Gomez M(2015) Prevention of hepatocellular carcinoma by correction of metabolic abnormalities: Role of statins and metformin World J Hepatol 7: 1105-1111 [PMID: 26052399]

Interaction Information:

Comment Statins are 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors. Additionally to the effect on cho­lesterol biosynthesis, statins also have antineoplastic properties. Antitumoral effects of statins are related to the following mechanisms: (1) they can effectively downregulate the RAF/MEK/ERK pathway, contributing to the apoptotic response; (2) statins limit the degradation of the cyclin-dependent kinase inhibitors p21 and p27. These molecules show growth-inhibitory effects; (3) HMG-CoA reductase is a crucial regulator of MYC phosphorylation and activation. Consequently, inhibition of HMG-CoA reductase prevents from both c-Myc phosphorylation and activation; and (4) anti-inflammatory and antioxidant effects of statins may be partly mediated by the PI3K/AKT pathway, causing a decline in toll-like receptor 4 expression on blood monocytes and TNFalpha plasma concentration.
Formal Description
Interaction-ID: 59753

drug/chemical compound

Statin

decreases_activity of